Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Ouattara, Eric ^a,b,c   Danel, Christine ^a,b,c   Moh, Raoul ^a,b,c   Gabillard, Delphine ^a,b,c   Peytavin, Gilles ^d   Konan, Romuald ^a   Le Carrou, Jérome ^a,b,c   Bohoussou, Franck ^a   Eholie, Serge P ^a,e   Anglaret, Xavier ^a,b,c  

^a Programme PAC CI   (Côte d’Ivoire)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d BICHAT HOSPITAL   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

Author keywords

3 nucleoside reverse transcriptase inhibitors; Adults; Antiretroviral treatment; Early treatment; HIV infection; Side effects; Sub Saharan Africa; Tolerance

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HEMOGLOBIN; ZIDOVUDINE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COTE D'IVOIRE; DELIRIUM; DIZZINESS; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NAUSEA; NAUSEA AND VOMITING; NEPHROTIC SYNDROME; NIGHTMARE; PATIENT HISTORY OF THERAPY; PILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL TRACT; 3 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; ADULTS; ANTIRETROVIRAL TREATMENT; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG TOXICITY; EARLY TREATMENT; GASTROINTESTINAL DISEASE; IMMUNOLOGY; METHODOLOGY; MULTICENTER STUDY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECTS; SUB-SAHARAN AFRICA; TOLERANCE;

3 NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS; ADULTS; ANTIRETROVIRAL TREATMENT; EARLY TREATMENT; HIV INFECTION; SIDE EFFECTS; SUB-SAHARAN AFRICA; TOLERANCE;

ADENINE; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COTE D'IVOIRE; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GASTROINTESTINAL DISEASES; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; ZIDOVUDINE;

EID: 84887276559     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18059     Document Type: Article

References (29)

1. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, Duvignac J, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. Aids. 2008;22(7):873-82.
2. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. Aids. 2011;25(6):851-5.
3. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Aids. 2008;22(15):1897-908.
4. WHO. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2010 revision. [cited 2011 May 12]. Available from: http://whqlibdoc.who.int/publications/2010/9789241599764- eng.pdf
5. Cuzin L, Pugliese P, Bugnon F, Delpierre C, Cua E, Billaud E, et al. Triple nucleoside reverse transcriptase inhibitor vs. non-nucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. HIV Med. 2005;6(6):388-95.
6. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350(18):1850-61.
7. Masquelier B, Neau D, Boucher S, et al. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients. Antivir Ther. 2006;11(6):827-30.
8. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
9. Munderi P,Walker AS, Kityo C, Babiker AC, Ssali F, Reid A, et al. Nevirapine/ zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010;11(5):334-44.
10. Good SS, Reynolds DJ, de Miranda P. Simultaneous quantification of zidovudine and its glucuronide in serum by high-performance liquid chromatography. J Chromatogr. 1988;431(1):123-33.
11. Langtry HD, Campoli-Richards DM. Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs. 1989;37(4):408-50.
12. Agence Nationale de recherche sur le Sida et les hépatites virales (ANRS). Echelle ANRS de cotation de la gravité des évé nements indésirables chez l'adulte. Version no6 du 9 Septembre 2003. [cited 2012 July 16]. Available from: http://www.anrs.fr/content/download/1537/ 10048/file/ANRS-GradeEI-V6-Fr-2003.pdf
13. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther. 2002;24(10):1502-14.
14. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34(8):1137-42.
15. Yarchoan R, Mitsuya H, Myers CE, Broder S. Clinical pharmacology of 3'-azido-2', 3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med. 1989;321(11):726-38.
16. Dart Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. Aids. 2006;20(10):1391-9.
17. Luque A, Hulse S, Wang D, Shahzad U, Tanzman E, Antenozzi S, et al. Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus. Infect Control Hosp Epidemiol. 2007;28(6):695-701.
18. Winston A, McAllister J, Amin J, Cooper DA, Carr A. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med. 2005;6(3):191-7.
19. Mengelers MJ, Van Gogh ER, Kuiper HA, Pijpers A, Verheijden JH, Van Miert AS. Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. J Vet Pharmacol Ther. 1995;18(4):243-53.
20. Jacobson MA, Gundacker H, Hughes M, Fischl M, Volberding P. Zidovudine side effects as reported by black, Hispanic, and white/non-Hispanic patients with early HIV disease: combined analysis of two multicenter placebocontrolled trials. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(1):45-52.
21. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003;3(3):136-58.
22. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics. 1999;9(5):591-9.
23. Burger DM, Meenhorst PL, Koks CH, Beijnen JH. Drug interactions with zidovudine. Aids. 1993;7(4):445-60.
24. Chatton JY, Munafo A, Chave JP, Steinhäuslin F, Roch-Ramel F, Glauser MP, et al. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol. 1992;34(6):551-4.
25. Dallas S, Read SE, King S, Koren G, Bendayan R. Pharmacokinetic interaction between zidovudine and trimethoprim/sulphamethoxazole in HIV-1 infected children. Can J Infect Dis. 2000;11(5):254-8.
26. Lee BL, Safrin S, Makrides V, Gambertoglio JG. Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1996;40(5):1231-6.
27. Macleod R, Eagling VA, Sim SM, Back DJ. In vitro inhibition studies of the glucuronidation of 3′-azido-3′-deoxythymidine catalysed by human liver UDP-glucuronosyl transferase. Biochem Pharmacol. 1992;43(2):382-6.
28. Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol. 1991;32(1):17-21.
29. Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A, et al. Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Cote d'Ivoire. Antivir Ther. 2005;10(5):615-24.